Travere Therapeutics' market cap has more than doubled in six months, reflecting confidence in FILSPARI's role in treating ...

Travere Therapeutics stock has doubled, and then some, in 2025 even as competition heats up for its bread-and-butter drug, ...

Travere Therapeutics stock tanked yesterday as the company reported its kidney disease drug FILSPARI had failed to meet its key endpoint in a confirmatory study. TVTX shares fell to ~$8 - down 40% for ...

Travere Therapeutics (NASDAQ:TVTX) underwent analysis by 14 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ...

A healthcare hedge fund just locked in gains on one of its biggest winners—here’s what that move really signals.

Fintel reports that on November 28, 2025, HC Wainwright & Co. reiterated coverage of Travere Therapeutics (NasdaqGM:TVTX) ...

Travere Therapeutics’ kidney disease strategy has hit a snag. A pivotal phase 3 trial of sparsentan missed its primary endpoint, but the biotech is undeterred, outlining plans to talk to the FDA about ...

Travere said that Filspari was promising in preserving kidney function. The therapy did not meet all of its endpoints in a phase 3 trial. Travere recently sold two of its drugs for $445 million.

Thinking about what to do with your Travere Therapeutics stock? You are not alone. The past few months have been busy for this biotech name, giving investors new reasons to pay attention. Maybe you ...

4 analysts have expressed a variety of opinions on Travere Therapeutics (NASDAQ:TVTX) over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent ...

Travere Therapeutics, Inc. (NASDAQ:TVTX) shares are trading higher on Wednesday after the company announced that it was informed by the FDA that an advisory committee is no longer needed following ...